Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke.
Concerns have arisen about possible effects of protease inhibitors (PIs) on cardiac conductivity. We found no significant association between current or recent PI exposure and sudden death or nonhemorrhagic stroke (adjusted rate ratio, 1.22; 95% confidence interval, .95-1.57), whereas cumulative exposure to PIs was associated with an increased risk (adjusted rate ratio, 1.06 per year of exposure; 95% confidence interval, 1.01-1.11).
Copenhagen HIV Programme, University of Copenhagen, Denmark. sww@cphiv.dk
S W
SW
Worm
D A
DA
Kamara
P
P
Reiss
E
E
Fontas
S
S
De Wit
W
W
El-Sadr
A
A
D'Arminio Monforte
M
M
Law
A
A
Phillips
L
L
Ryom
F
F
Dabis
R
R
Weber
C
C
Sabin
J D
JD
Lundgren
D000328:Adult; D003645:Death, Sudden / Q000453:epidemiology*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D020521:Stroke / Q000453:epidemiology* / Q000401:mortality*
D017320:HIV Protease Inhibitors